We serve Chemical Name:(1-ethoxy-2-methylprop-1-enoxy)-trimethylsilane CAS:31469-16-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(1-ethoxy-2-methylprop-1-enoxy)-trimethylsilane
CAS.NO:31469-16-6
Synonyms:1-ethoxy-2-methyl-1-trimethylsiloxyprop-1-ene;[(1-Ethoxy-2-methyl-1-propen-1-yl)oxy](trimethyl)silane;Silane, [(1-ethoxy-2-methyl-1-propen-1-yl)oxy]trimethyl-;trimethylsilyl enol ether of ethyl isobutyrate
Molecular Formula:C9H20O2Si
Molecular Weight:188.339
HS Code:2931900090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:182.4±23.0 °C at 760 mmHg
Density:0.9±0.1 g/cm3
Index of Refraction:1.423
PSA:18.46000
Exact Mass:188.123260
LogP:3.80
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-ethoxy-2-methyl-1-trimethylsiloxyprop-1-ene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,trimethylsilyl enol ether of ethyl isobutyrate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-ethoxy-2-methyl-1-trimethylsiloxyprop-1-ene Use and application,Silane, [(1-ethoxy-2-methyl-1-propen-1-yl)oxy]trimethyl- technical grade,usp/ep/jp grade.
Related News: The workers are demanding that Hong Kong close all border checkpoints to visitors from mainland China, saying they represent a threat to health care workers in the city. (1-ethoxy-2-methylprop-1-enoxy)-trimethylsilane manufacturer Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. (1-ethoxy-2-methylprop-1-enoxy)-trimethylsilane supplier Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. (1-ethoxy-2-methylprop-1-enoxy)-trimethylsilane vendor Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). (1-ethoxy-2-methylprop-1-enoxy)-trimethylsilane factory Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.
